JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M703018200 on May 16, 2007

J. Biol. Chem., Vol. 282, Issue 27, 19510-19517, July 6, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/27/19510    most recent
M703018200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choi, M.-M.
Right arrow Articles by Huh, J.-W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choi, M.-M.
Right arrow Articles by Huh, J.-W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Amino Acid Changes within Antenna Helix Are Responsible for Different Regulatory Preferences of Human Glutamate Dehydrogenase Isozymes*

Myung-Min Choi{ddagger}, Eun-A Kim{ddagger}, Seung-Ju Yang§, Soo Young Choi, Sung-Woo Cho{ddagger}1, and Jae-Wan Huh{ddagger}2

From the {ddagger}Department of Biochemistry and Molecular Biology, University of Ulsan College of Medicine, Seoul 138-736, Korea, §Department of Biomedical Laboratory Science, Konyang University, Daejeon 302-718, Korea, and Department of Biomedical Sciences, Hallym University, Chunchon 200-702, Korea

Received for publication, April 10, 2007 , and in revised form, May 14, 2007.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Human glutamate dehydrogenase (hGDH) exists in hGDH1 (housekeeping isozyme) and in hGDH2 (nerve-specific isozyme), which differ markedly in their allosteric regulation. Because they differ in only 16 of their 505 amino acids, the regulatory preferences must arise from amino acid residues that are not common between hGDH1 and hGDH2. To our knowledge none of the mutagenesis studies on the hGDH isozymes to date have identified the amino acid residues fully responsible for the different regulatory preferences between hGDH1 and hGDH2. In this study we constructed hGDH1(hGDH2390–448)hGDH1 (amino acid segment 390–448 of hGDH1 replaced by the corresponding hGDH2 segment) and hGDH2(hGDH1390–448)hGDH2 (amino acid segment 390–448 of hGDH2 replaced by the corresponding hGDH1 segment) by swapping the corresponding amino acid segments in hGDH1 and hGDH2. The chimeric enzymes by reciprocal swapping resulted in double mutations in amino acid sequences at 415 and 443 residues that are not common between hGDH1 and hGDH2 and are located in the C-terminal 48-residue "antenna" helix, which is thought to be part of the regulatory domain of mammalian GDHs. Functional analyses revealed that the doubly mutated chimeric enzymes almost completely acquired most of the different regulatory preferences between hGDH1 and hGDH2 for electrophoretic mobility, heat-stability, ADP activation, palmitoyl-CoA inhibition, and L-leucine activation, except for GTP inhibition. Our results indicate that substitutions of the residues in the antenna region may be important evolutionary changes that led to the adaptation of hGDH2 to the unique metabolic needs of the nerve tissue.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Glutamate dehydrogenase (GDH)3 is found in all organisms and catalyzes the oxidative deamination of glutamate to 2-oxoglutarate. Although this enzyme does not exhibit allosteric regulation in plants, bacteria, or fungi, its activity is tightly controlled by a number of compounds in mammals (1–6). All mammalian GDHs are homohexameric, exhibiting 32 symmetry, and the first 200 residues form the core "glutamate binding" domain. On top of this domain is a "NAD binding" domain that rotates about 20° during catalysis (7–9). Unique to the animal structures is a 48-residue antenna that protrudes above this NAD binding domain (7–9).

Various roles of GDH have been reported. Partial deficiency of GDH has been reported in some patients with cerebellar degeneration, suggesting that the enzymes are important in brain function (10). GDH has shown neuroprotective value in model systems where glutamate reuptake is inhibited (11). In addition, it has been reported that inhibition of GDH expression by antisense oligonucleotides was toxic to cultured mesencephalic neurons, with dopaminergic neurons being affected at the early stages of this inhibition (12). The existence of the hyperinsulinism-hyperammonemia syndrome further highlights the importance of GDH in the regulation of insulin secretion and indicates that GDH has an important role in regulating hepatic ureagenesis (13, 14).

In the human, GDH exists in a housekeeping isozyme (hGDH1) encoded by the GLUD1 gene and a neural and testicular tissue-specific isozyme (hGDH2) encoded by the GLUD2 gene (15). Although the two GDH isozymes are highly homologous (showing a 97% amino acid identity), they differ markedly in their regulatory properties such as heat stability and allosteric regulation by ADP, L-leucine, and GTP (3–6, 16, 17). Because the hGDH isozymes differ in only 16 of their 505 amino acids, these functional differences must arise from amino acid residues that are not common between hGDH1 and hGDH2. Reciprocally interchanging amino acids that are different between hGDH isozymes within the regulatory domain may reveal the residues important for preference in hGDH isozymes. Recent studies of structure-function relationships using site-directed mutagenesis of hGDH1 at single sites differing from hGDH2 showed that the R443S and the G456A change reproduced some but not all of the properties of hGDH2 (3–5, 17). In addition, several other residues differing between hGDH isozymes also have been examined by many investigators (4, 17). Very recently, Kanavouras et al. (6) created a double hGDH1 mutant differing from hGDH2 and showed that the double-mutated enzyme with R443S and G456A in the same polypeptide chain did not acquire all the characteristics of the wild-type hGDH2. These results suggest that additional amino acid changes should be responsible for the unique properties of the brain-specific hGDH2 isozyme. To our knowledge, none of the single or multiple mutagenesis studies on the hGDH isozymes up to date have identified the amino acid residues fully responsible for the different regulatory properties between the hGDH1 and hGDH2.

Our objective is to identify these critical residues by multiple mutagenesis. In this study we selected two such residues, Met-415 and Arg-443, because they are the only two amino acid residues that are different between hGDH1 and hGDH2 within the C-terminal 48-residue antenna region, which is thought to be part of the regulatory domain of mammalian GDH (7–9). Using cassette mutagenesis, we constructed hGDH1(hGDH2390–448)hGDH1 (amino acid segment 390–448 of hGDH1 replaced by the corresponding hGDH2 segment) and hGDH2(hGDH1390–448)hGDH2 (amino acid segment 390–448 of hGDH2 replaced by the corresponding hGDH1 segment) by swapping the corresponding amino acid segments between 390 and 448 regions in hGDH1 and hGDH2. The mutated cDNAs were expressed in Escherichia coli as soluble proteins, and the chimeric forms of hGDH isozymes were purified to homogeneity and studied with respect to their kinetic and regulatory characteristics. The functional and evolutionary implications of these findings are discussed.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Materials—ADP, GTP, palmitoyl-CoA, and L-leucine were purchased from Sigma-Aldrich. 2,5-ADP-Sepharose and Resource-Q were purchased from Amersham Biosciences. Restriction enzymes were purchased from New England Biolabs. All other chemicals and solvents were reagent grade or better. E. coli DH5{alpha} (18) was purchased from Invitrogen and used as the host strain for plasmid-mediated transformations for cassette mutagenesis. E. coli PA340 (thr-1 fhuA2 leuB6 lacY1 supE44 gal-6 gdh-1 hisG1 rfbD1 galP63 {Delta}(gltB-F)500 rpsL19 malT1 xyl-7 mtl-2 argH1 thi-1; kindly provided by Dr. Mary K.B. Berlyn, E. coli Genetic Stock Center, Yale University, New Haven, CT) lacked both GDH and glutamate synthase activities (19) and was used to test plasmids for GDH activity. E. coli BL21 (DE3) (20) was used for high level expression of the recombinant enzymes.

Construction of hGDH1(hGDH2390–448)hGDH1 and hGDH2(hGDH1390–448)hGDH2 Chimeric Enzymes—Using cassette mutagenesis, we created two double mutations, each containing both of two amino substitutions at 415 and 443 sites in the same polypeptide chain. The strategy to construct the chimeric enzymes is shown in Fig. 1. Synthetic hGDH1 and hGDH2 genes used in this study were previously constructed in our laboratory (4, 21). Using cassette mutagenesis, the construction of hGDH1(hGDH2390–448)hGDH1 (amino acid segment 390–448 of hGDH1 replaced by the corresponding hGDH2 segment) and hGDH2(hGDH1390–448)hGDH2 (amino acid segment 390–448 of hGDH2 replaced by the corresponding hGDH1 segment) was carried out by swapping the corresponding amino acid segments between 390 and 448 regions in hGDH1 and hGDH2. For this construct, the plasmids containing hGDH1 gene (21) and hGDH2 gene (4) were separately double-digested with AflII and NheI, and the large and small fragments were isolated from the agarose gel. The small and large fragments were then cross-ligated to produce the chimeric constructs hGDH1(hGDH2390–448)GDH1 and hGDH2(hGDH1390–448)GDH2. The successful construction of the chimeric enzymes was confirmed by dideoxy-DNA sequencing analysis.

Expression and Purification of Chimeric Enzymes—The chimeric constructs were separately transformed into E. coli/DE3 for overexpression. Fresh overnight cultures of the E. coli/DE3 were used to inoculate 1 liter of LB medium containing 100 µg/ml ampicillin. The cell was grown at 37 °C until the A600 reached 1.0, and then isopropyl 1-thio-beta-D-galactopyranoside was added to a final concentration of 1 mM. After isopropyl 1-thio-beta-D-galactopyranoside induction, each E. coli/DE3 was grown for an additional 3 h at 37 °C and then harvested by centrifugation. Cell pellets were suspended in 50 ml of 50 mM Tris-HCl, pH 7.2, 1 mM phenylmethylsulfonyl fluoride and lysed with a sonicator. Cellular debris was removed by centrifugation, and the crude extracts were loaded onto an 2,5-ADP-Sepharose column (1.5 x 5 cm) that was equilibrated with buffer A (50 mM Tris-HCl, pH 7.2, and 1 mM beta-mercaptoethanol). The column was washed with buffer A until the breakthrough peak of protein had been eluted. The enzyme was then performed using a NaCl step gradient that went from 0 to 300 mM in 30 min at a flow rate of 1 ml/min. The fractions containing GDH activity were pooled, concentrated, and applied to a fast protein liquid chromatograph Resource-Q anion exchange column equilibrated with buffer B (50 mM Tris-HCl, pH 8.0, 0.5 mM EDTA, and 1 mM beta-mercaptoethanol). The enzyme was then eluted using a linear gradient made with buffer B in increasing concentrations of NaCl up to 500 mM at 1 ml/min. The purified enzyme was analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western blot analysis using monoclonal antibodies previously produced in our laboratory (22). Protein concentration was determined by the method of Bradford (23). Additional N-terminal residues (MIEGR) were removed by treatment with factor Xa (10 µg/1 mg of GDH) and purified by a HPLC gel filtration method as described before (4, 21). HPLC-purified proteins were subjected to automated amino acid sequencing.

Enzyme Assay and Kinetics—Steady state kinetic parameters were determined with the purified proteins unless otherwise indicated. Enzyme assays were performed by monitoring reduced coenzyme absorbance at 340 nm. Because E. coli only has an NADP+-dependent GDH (19), the enzyme assay was performed with NADH as a coenzyme. All assays were performed in duplicate, and initial velocity data were correlated with a standard assay mixture of 1 ml containing 50 mM triethanolamine, pH 8.0, 100 mM ammonium acetate, 0.1 mM NADH, and 2 mM EDTA, pH 8.0, at 25 °C. Enzyme assay was performed in the presence of 1 mM ADP unless otherwise indicated. The reaction started with the addition of {alpha}-ketoglutarate to 2 mM final concentration. The Km values were calculated by linear regression analysis of double-reciprocal plots, and catalytic efficiency was estimated by use of the equation v/[E0] = (kcat/Km)[S] (24). For the heat stability studies, the hGDH isozymes were incubated at 45 °C in the absence of ADP. At various times, aliquots were withdrawn to determine remaining activities by the addition of the standard assay mixture in the presence of 1 mM ADP.

Regulation of Chimeric Enzymes—Effects of allosteric regulators on GDH activities were examined by incubating the enzyme with the allosteric effectors at various concentrations in the assay buffer at 25 °C. At intervals after the initiation with the effectors, aliquots were withdrawn for the assay of GDH activity. Regulation of the hGDH isozymes and the chimeric enzymes by ADP or L-leucine was studied by adding ADP (0–1 mM final concentrations) or L-leucine (0–5 mM final concentrations) to the reaction mixture at various concentrations while keeping the other substrates constant. We also explored the effect of ADP and L-leucine used together at various concentrations on hGDH isozymes and chimeric mutants. ADP (0–1 mM) was added to the reaction mixture that contained L-leucine at various concentrations (0–5 mM). GTP inhibition and palmitoyl-CoA inhibition were studied by adding GTP (0–100 µM final concentrations) or palmitoyl-CoA (0–10 µM final concentrations) at various concentrations to the standard reaction mixture in the presence of 1 mM ADP. For the thermal stability studies, the wild-type and chimeric enzymes were incubated in 100 mM potassium phosphate buffer, pH 7.0 at 45 °C in the presence of 1 mM ADP. At various times, aliquots were withdrawn, and the remaining activities were assayed by the addition of the standard assay mixture.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Construction, Expression, and Purification of hGDH1-(hGDH2390–448)hGDH1 and hGDH2(hGDH1390–448)hGDH2 Chimeric Enzymes—We have reported construction of synthetic hGDH1 and hGDH2 genes and expression of hGDH1 and hGDH2 isozymes from E. coli as soluble proteins (4, 21). Using cassette mutagenesis, the construction of hGDH1(hGDH2390–448)hGDH1 (amino acid segment 390–448 of hGDH1 replaced by the corresponding hGDH2 segment) and hGDH2(hGDH1390–448)hGDH2 (amino acid segment 390–448 of hGDH2 replaced by the corresponding hGDH1 segment) was carried out by swapping the corresponding amino acid segments in hGDH1 and hGDH2 (Fig. 1). The chimeric enzymes by reciprocal swapping resulted in double mutations in amino acid sequences at 415 and 443 residues that are not common between hGDH1 and hGDH2. In the wild-type hGDH isozymes, the 415 site is Met in hGDH1 and Leu in hGDH2, and the 443 site is Arg in hGDH1 and Ser in hGDH2. In hGDH1(hGDH2390–448)hGDH1, the 415 site is Leu and the 443 site is Ser, whereas in hGDH2(hGDH1390–448)hGDH2, the 415 site is Met and the 443 site is Arg (Fig. 1).

High level expression of the chimeric enzymes was achieved in E. coli strain DE3 upon induction with 1 mM isopropyl-L-D-thiogalactose at 37 °C for 3 h. Analysis of crude cell extracts by Western blot showed that expression levels of hGDH1(hGDH2390–448)hGDH1 and hGDH2(hGDH1390–448)hGDH2 were almost identical to those of wild-type hGDH isozymes (data not shown). The expressed enzymes were purified by ADP-Sepharose column and fast protein liquid chromatograph Resource-Q column. To remove five additional N-terminal residues (MIEGR) that were introduced to create an initiation codon and a factor Xa recognition site, the purified enzymes were treated with factor Xa, purified by an HPLC Protein-Pak 300SW gel filtration column, and subjected to automated Edman degradation. N-terminal sequence analysis of the first eight amino acids was identical with the published sequence of the mature hGDH isozymes (15, 25). The purified wild-type hGDH2 was estimated to be ~96% pure by SDS-PAGE (Fig. 2A). Compared with hGDH1, the hGDH2 protein is more basic and shows a slightly lower electrophoretic mobility (Fig. 2A). These differences are consistent with the electrophoretic characteristics of hGDH isozymes as reported by other investigators (15). Interestingly, when the amino acid segment 390–448 of hGDH1 was replaced by the corresponding hGDH2 segment to make hGDH1(hGDH2390–448)hGDH1, it was found to show the same electrophoretic mobility as hGDH2 (Fig. 2A). Likewise, when the amino acid segment 390–448 from the hGDH1 is spliced onto human GDH2, the electrophoretic mobility of hGDH2(hGDH1390–448)hGDH2 was almost identical to that of hGDH1. These results suggest that the amino acid differences at 415 and 443 sites within the antenna region are responsible for the electrophoretic mobility of the hGDH isozymes.


Figure 1
View larger version (17K):
[in this window]
[in a new window]

  		FIGURE 1.
Construction of hGDH1(hGDH2390–448)hGDH1 and hGDH2(hGDH1390–448)hGDH2 chimeric enzymes. hGDH1 and hGDH2 are represented by an open box and a filled box, respectively. Locations of restriction sites are shown as the amino acid number underneath. Locations of the double mutations at 415 and 443 sites are indicated by {blacktriangledown}.

 
Heat Stability of hGDH1(hGDH2390–448)hGDH1 and hGDH2(hGDH1390–448)hGDH2—The relative resistance of hGDH2 to thermal inactivation was determined by incubation of the enzyme at 45 °C, pH 7.0. Heat inactivation proceeded faster for hGDH2 (half-life = 45 min) than for hGDH1 (half-life = 310 min) (Fig. 2B), supporting the previous observation that hGDH1 is the heat-stable form, and hGDH2 is the heat-labile form of human GDH (4, 16). Under these conditions, the hGDH1(hGDH2390–448)hGDH1 and hGDH2(hGDH1390–448)hGDH2 chimeric enzymes showed the reciprocal changes in thermal stability of hGDH isozymes. hGDH2(hGDH1390–448)hGDH2 abolished the heat lability of hGDH2 and changed the half-life of hGDH2 from 45 to ~280 min at 45 °C, which is comparable with that of hGDH1 (Fig. 2B). In contrast, hGDH1(hGDH2390–448)hGDH1 abolished the heat stability of hGDH1, and the result obtained with hGDH1(hGDH2390–448)hGDH1 was similar to that observed with hGDH2 (Fig. 2B). Previously, we reported that single replacement of Ser by Arg at hGDH2 position 443 abolished the heat lability of hGDH2 and changed the half-life of hGDH2 to almost the same as that of hGDH1, whereas single mutagenesis at several other sites (L415M, A456G, and H470R) that are different between hGDH1 and hGDH2 did not show any change in thermal stability (5). Therefore, the influence of heat stability on hGDH isozymes caused by swapping amino acid segment 390–448 is mainly due to the difference of the amino acid at the 443 site, which is Arg in hGDH1 and Ser in hGDH2.


Figure 2
View larger version (48K):
[in this window]
[in a new window]

  		FIGURE 2.
A, 8% SDS-PAGE analysis of the purified hGDH isozymes and chimeric enzymes. Lane 1, prestained marker proteins (Novex); lane 2, wild-type hGDH1; lane 3, hGDH1(hGDH2390–448)hGDH1; lane 4, wild-type hGDH2; lane 5, hGDH2(hGDH1390–448)hGDH2. B, thermal stability of the purified hGDH isozymes and chimeric enzymes. Data points represent the mean values from at least two experimental determinations and are expressed as the percentage of base-line activity (no heat added). Enzymes were incubated at 45 °C in 100 mM sodium phosphate buffer, pH 7.0, in the absence of ADP. At various times aliquots were withdrawn, and the remaining activity was assayed in the standard assay mixture at pH 8.0 in the presence of 1 mM ADP. hGDH1 wild-type ({blacksquare}), hGDH1(hGDH2390–448)hGDH1 ({square}), hGDH2 wild-type ({blacktriangleup}), and hGDH2(hGDH1390–448)hGDH2 ({triangleup}).

 
Catalytic Properties of hGDH1(hGDH2390–448)hGDH1 and hGDH2(hGDH1390–448)hGDH2—To evaluate more detailed catalytic properties for the wild-type hGDH isozymes and the chimeric enzymes, the enzyme efficiencies (kcat/Km) for the individual substrates were determined. The catalytic and kinetic properties of hGDH1(hGDH2390–448)hGDH1 and hGDH2(hGDH1390–448)hGDH2 were not altered. The apparent Km values for {alpha}-ketoglutarate and NADH were essentially similar for all wild-type and mutant proteins as of 79 ~ 86 µM and 1.25 ~ 1.39 mM for NADH and {alpha}-ketoglutarate, respectively (Table 1). These results suggest that substitutions at position 415 and 443 site might have no appreciable effect on the affinity of hGDH isozymes for both substrate and coenzyme. However, there was an ~30% increase in kcat values of wild-type hGDH2 (130 s–1) and hGDH2(hGDH1390–448)hGDH2 (127 s–1) compared with that of the wild-type hGDH1 (104 s–1) and hGDH1(hGDH2390–448)hGDH1 (105 s–1). The increased enzyme efficiency (kcat/Km) of wild-type hGDH2 and hGDH2(hGDH1390–448)hGDH2, therefore, results from the increase in kcat values. Western blot analysis showed that expression levels of hGDH1(hGDH2390–448)hGDH1 and hGDH2(hGDH1390–448)hGDH2 were almost identical to those of wild-type hGDH isozymes (data not shown). In addition, hGDH1(hGDH2390–448)hGDH1 and hGDH2(hGDH1390–448)hGDH2 were purified by the same methods as was the wild-type hGDH isozymes, indicating that no gross conformational change in the chimeric enzymes had occurred. Therefore, the difference in the kcat values between hGDH1 and hGDH2 is probably not due to the amino acid differences at 415 and 443 sites within the antenna region but due to the rest of the amino acids not common between hGDH1 and hGDH2.


View this table:
[in this window]
[in a new window]

  		TABLE 1
Kinetic properties of hGDH isozymes and chimeric enzymes

Km and kcat/Km values of wild-type hGDH isozymes and chimeric enzymes were obtained from the initial velocity data and linear regression analysis of double-reciprocal plots as described under "Experimental Procedures." GDH activity was measured in the presence of 1 mM ADP. The data represent the means of two independent experiments. Duplicate of the kinetic values differed less than 5%. {alpha}-KG, {alpha}-ketoglutarate.

 
Inhibition of hGDH1(hGDH2390–448)hGDH1 and hGDH2(hGDH1390–448)hGDH2 by Palmitoyl-CoA—Palmitoyl-CoA induced a concentration-dependent inhibition of hGDH isozymes. Palmitoyl-CoA especially exerted a power inhibitory effect on the hGDH2. In contrast, hGDH1 was less sensitive to palmitoyl-CoA inhibition. When the segment 390–448 from the hGDH2 is spliced onto human GDH1 to make hGDH1(hGDH2390–448)hGDH1, it was found to show almost identical sensitivity to palmitoyl-CoA inhibitory aspects of hGDH2 (Fig. 3A). In contrast, hGDH2(hGDH1390–448)hGDH2 resulted in the resistance to palmitoyl-CoA inhibition that is comparable with that of wild-type hGDH1 (Fig. 3A). These results suggest that the amino acid differences at 415 and 443 sites within the antenna region are responsible for the different sensitivity to inhibition by palmitoyl-CoA of hGDH1 and hGDH2.


Figure 3
View larger version (20K):
[in this window]
[in a new window]

  		FIGURE 3.
A, palmitoyl-CoA inhibition curves of the purified hGDH isozymes and chimeric enzymes. Data points represent mean values from at least two experimental determinations and are expressed as the percentage of baseline activity (no palmitoyl-CoA added). GDH activity was measured in the standard assay mixture in the presence of increasing concentrations of palmitoyl-CoA. All assays were performed in the presence of 1 mM ADP. B, ADP activation curves of the purified hGDH isozymes and chimeric enzymes. Data points represent mean values from at least two experimental determinations and are expressed as the percentage of maximal activity. GDH activity was measured in the standard assay mixture in the presence of increasing concentrations of ADP. hGDH1 wild-type ({blacksquare}), hGDH1(hGDH2390–448)hGDH1 ({square}), hGDH2 wild-type ({blacktriangleup}), and hGDH2(hGDH1390–448)hGDH2 ({triangleup}).

 
Activation of hGDH1(hGDH2390–448)hGDH1 and hGDH2(hGDH1390–448)hGDH2 by ADP—There were differences in the sensitivity to ADP between hGDH1 and hGDH2. Although hGDH1 was activated by ADP at a hyperbolic manner, the ADP stimulatory curves of hGDH2 showed a sigmoidal pattern typically found in allosteric regulation. When the segment 390–448 from the hGDH1 is spliced onto hGDH2 to make hGDH2(hGDH1390–448)hGDH2, it was found to show almost identical sensitivity to ADP regulatory aspects of hGDH1 (Fig. 3B). Similarly, replacing amino acid segment 390–448 of hGDH1 with the corresponding region of hGDH2 to produce chimeric hGDH1(hGDH2390–448)hGDH1 resulted in the activation by ADP at a sigmoidal manner that is comparable with that of wild-type hGDH2 but substantially different from that of the wild-type hGDH1 (Fig. 3B). These results indicate that reciprocally switching amino acids at 415 and 443 sites influences preferences of the hGDH isozymes to ADP activation.


Figure 4
View larger version (25K):
[in this window]
[in a new window]

  		FIGURE 4.
L-Leucine activation curves of the purified hGDH isozymes and chimeric enzymes. During each set of experiments (each represented by a different curve), ADP concentration was kept constant at 0.0 mM ({blacksquare}), 0.1 mM ({circ}), and 0.5 mM ({triangleup}), whereas L-leucine varied from 0 to 10 mM. Data points represent mean values from at least two experimental determinations and are expressed as percentage of maximal activity. A, hGDH1 wild-type; B, hGDH2 wild-type; C, hGDH1(hGDH2390–448)hGDH1; D, hGDH2(hGDH1390–448)hGDH2.

 
Activation of hGDH1(hGDH2390–448)hGDH1 and hGDH2(hGDH1390–448)hGDH2 by M-Leucine—When enzyme assays were performed without ADP, the addition of L-leucine up to 5 mM enhanced the activity of the hGDH isozymes with a proportionally greater stimulation of hGDH2 than of hGDH1 (Fig. 4, A and B). In the absence of ADP, hGDH1 was activated by L-leucine in a hyperbolic manner (Fig. 4A), whereas the L-leucine stimulatory curves of hGDH2 showed a sigmoidal pattern (Fig. 4B). However, the presence of ADP abolished the differences in sensitivity to L-leucine of hGDH isozymes and similarly sensitized both hGDH1 and hGDH2 to the stimulatory effects of L-leucine. At 0.1 and 0.5 mM ADP, the L-leucine stimulatory curves of both hGDH1 and hGDH2 were hyperbolic with similar SC50 values. In the absence of ADP, the chimeric hGDH1(hGDH2390–448)hGDH1 reduced the basal activity as low as hGDH2 and influenced the sensitivity to L-leucine activation with a conversion of the hyperbolic curve into the sigmoidal curve (Fig. 4C). Similarly, the L-leucine stimulatory curves of hGDH2(hGDH1390–448)hGDH2 increased a basal activity almost up to that of hGDH1 (Fig. 4D). In addition to increasing basal activity, hGDH2(hGDH1390–448)hGDH2 showed a hyperbolic pattern in the presence and absence of ADP (Fig. 4D) that is comparable with that of wild-type hGDH1 (Fig. 4A) but clearly different from that of the wild-type hGDH2 (Fig. 4B). These results with the chimeric enzymes suggest that the amino acid differences at 415 and 443 sites are responsible for the different sensitivity to activation by L-leucine of hGDH1 and hGDH2.

Inhibition of hGDH1(hGDH2390–448)hGDH1 and hGDH2(hGDH1390–448)hGDH2 by GTP—Studies of the GTP inhibition on enzyme activity revealed that hGDH2 was resistant to GTP inhibition, whereas hGDH1 was potently inhibited by this compound (Fig. 5). Interestingly, unlike to the results in ADP or L-leucine activation studies, the reciprocal changes in the sensitivity to GTP inhibition were not observed when GTP inhibition studies were performed with the chimeric isozymes (Fig. 5). Therefore, the difference in the sensitivity to GTP inhibition between hGDH1 and hGDH2 is probably not due to the amino acid differences at 415 and 443 sites within the antenna region but due to the rest of the amino acids not common between hGDH1 and hGDH2.


Figure 5
View larger version (17K):
[in this window]
[in a new window]

  		FIGURE 5.
GTP inhibition curves of the purified hGDH isozymes and chimeric enzymes. Data points represent mean values from at least two experimental determinations and are expressed as percentage of baseline activity (no GTP added). GDH activity was measured in the standard assay mixture in the presence of increasing concentrations of GTP. All assays were performed in the presence of 1 mM ADP. hGDH1 wild-type ({blacksquare}), hGDH1(hGDH2390–448)hGDH1 ({square}), hGDH2 wild-type ({blacktriangleup}), and hGDH2(hGDH1390–448)hGDH2 ({triangleup}).

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
There is evolutionary evidence that GLUD2 is an X-linked intronless gene and originated by retroposition from GLUD1 in the hominoid ancestor less than 23 million years ago (28). GLUD2 is an unusual example of a gene that emerged as an intronless duplicate of GLUD1 on chromosome 10 by retro-transposition of its mRNA, achieved specialized expression in the brain, and then acquired multiple amino acid changes to facilitate its functioning in the brain such as resistance to the high GTP levels and a markedly increased activity dependence on ADP and L-leucine. Burki and Kaessmann (28) have suggested that these features allow instant activation of the enzyme in the brain when there is high frequency firing of neurons. Previous studies showed that GDH activities were differentially altered in neurologic patients (29, 30), thus suggesting that these activities are under different genetic control. Because electroretinographic abnormalities have been detected in patients with spinocerebellar ataxia who have a selective deficiency of the heat-labile GDH isozymes (10, 31–34), studies on the molecular basis for the different molecular properties of the GDH isozymes may, thus, be of importance for understanding the biology of the human nervous systems and the genetic analysis of X-linked neurodegeneration. Previously, two types of mitochondrial glutamate carrier (GC1 and GC2) were identified differing in their Vmax and Km values and in their tissue distribution (35). The GC1 is expressed in all tissues, whereas the GC2 is mainly expressed in the brain and in the testis. This tissue distribution is almost identical to that of the housekeeping hGDH1 and neural and testicular tissue-specific hGDH2, respectively. Because the transport of glutamate into the mitochondria is linked to its metabolism by GDH, it may be assumed that both hGDH2 and GC2 have adapted to the particular metabolic needs of the neural and testicular tissues where they are expressed.

Because hGDH1 and hGDH2 differs in only 16 of their 505 amino acids, there may be differences in the secondary or tertiary structure that could explain the different molecular properties of the hGDH isozymes and that the functional differences must arise from amino acid residues that are not common between the two isozymes. Reciprocally interchanging amino acids that are different between hGDH isozymes within the regulatory domain may reveal the residues important for preference in hGDH isozymes. Recent studies of structure-function relationships by many investigators (3–6, 8, 17, 36) have revealed several important residues differing between hGD1 and hGDH2 by using site-directed mutagenesis, including S331T, M370L, M415L, R443G, G456A, R463A, R470H, and N498S. However, the mutagenesis studies at these sites provide only partial but not all of regulatory preferences of hGDH isozymes.

X-ray crystal studies (7, 8, 37, 38) have shown that the regulatory domain of mammalian GDHs includes the pivot helix and the antenna (residues 401–448), a protruding structure composed of an ascending 23-residue {alpha}-helix and a descending strand (residues 425–448) ending with a small {alpha}-helix (residues 439–448). The 48-residue antenna region extends from the top of each NAD binding domain and intertwines with the antenna of two adjacent subunits, which may play an important role in GDH allosteric regulation (7, 8, 37, 38). In the antenna region there are two amino acids that are not common between hGDH1 and hGDH2. The 415 site is Met in hGDH1 and Leu in hGDH2, and the 443 site is Arg in hGDH1 and Ser in hGDH2. Previously, functional analyses of the single mutagenesis revealed that substitution of Leu for Met-415 had no effect on the catalytic or regulatory properties of the enzyme (36). We also have reported that L415M did not abolish the heat lability of hGDH2 (4). However, because Leu-415 and Arg-443 are located in the antenna region, we tested the possibility that the L415M substitution can act together with the R443S change to reproduce the unique properties of the isozymes. We have constructed hGDH1(hGDH2390–448)hGDH1 and hGDH2(hGDH1390–448)hGDH2, by reciprocally switching the corresponding amino acid segments 390–448 in hGDH1 and hGDH2 (Fig. 1). Functional analyses revealed that the doubly mutated chimeric enzymes acquired most of the different regulatory preferences between hGDH1 and hGDH2, such as electrophoretic mobility (Fig. 2A), heat stability (Fig. 2B), palmitoyl-CoA inhibition (Fig. 3A), ADP activation (Fig. 3B), and L-leucine activation (Fig. 4).

Palmitoyl-CoA inhibition appears to also be dependent upon the antenna domain. Our results showed that hGDH2 was more sensitized to palmitoyl-CoA inhibition than hGDH1 (Fig. 3A). In contrast to plants and fungi, animals perform {alpha}-oxidation of medium and long chain fatty acids mainly in the mitochondria, whereas the very long chain fatty acids are catabolized in the peroxisomes. Therefore, it has been proposed that the antenna evolved to link fatty acid and amino acid catabolism in the mitochondria (9). Previous studies have shown that mutations in the GTP and ADP binding regions do not affect palmitoyl-CoA inhibition (39). Although we do not yet know the location of the palmitoyl-CoA-binding site, it is tempting to speculate that palmitoyl-CoA might bind to the antenna domain and be inhibited by affecting the conformational changes associated with the opening and closing of the catalytic cleft (7).

It is clear that ADP activation is the most primitive form of allosteric activation, and the antenna-fewer mutants clearly demonstrates that it is dependent upon the antenna (9). Our results suggest that substitutions of the residues in the antenna region may be important evolutionary changes that led to the adaptation of hGDH2 to the unique metabolic needs of the nerve tissue. The fact that hGDH1(hGDH2390–448)hGDH1 totally abrogated activation of hGDH1 by L-leucine in the absence of ADP (Fig. 4C) is consistent with the possibility that the introduction of the hGDH2390–448 segment favors the closed enzyme conformation. L-Leucine is thought to bind at the active site (39), and therefore, closure of the catalytic cleft will prevent L-leucine from entering this region. The finding that ADP sensitized hGDH1(hGDH2390–448)hGDH1 to the stimulatory effect of L-leucine provides additional evidence that opening of the catalytic site (acting allosterically) by ADP is necessary for L-leucine to act.

Because we previously identified Lys-450 as a site for GTP binding (26, 27), it was not unexpected that the double mutations at 415 and 443 sites within the antenna region of hGDH2 were not influenced to facilitate GTP inhibition. However, as the antenna deletion and a number of the hyperinsulinism-hyper ammonemia mutations have shown (39–41), the antenna may have a function at least in part to communicate this inhibition. Previous studies showed that replacement of Gly-456 by Ala made hGDH1 resistant to GTP (3). The Gly-456 site lies about a one-and-a-half {alpha}-helix turns away from Lys-450, with the side chain of the former amino acid residue protruding out of the {alpha}-helix in the opposite direction than the side chain of the latter according to the proposed structural models (7, 37, 38). It is interesting to note that the G456A substitution seems to be conserved during mammalian evolution. The bovine liver GDH, like the human GLUD1 enzyme, contains Gly at position 452 (corresponds to Gly-456 in the human). Concerning the presence of Ala at this position in the human GLUD2, we separated two GDH isozymes from bovine brain and found by sequencing of isolated peptides that one of these isozymes contains Ala at position 452 (corresponding to Ala-456 in the human GLUD2) (26, 42).

Because GTP levels are generally higher in brain than in other tissues, GTP may not be a suitable modulator for hGDH2 activity in the nerve tissue. Taken together with the dependence on available ADP levels (3, 16), it will permit the recruitment of the enzyme under conditions of low energy charge (high ADP/ATP ratio), such as those occurring under intense glutamatergic neurotransmission (43). Therefore, hGDH2 may have evolved to function in the particular environment that prevails in glial cells after glutamate uptake.

In conclusion, except for different sensitivities to GTP inhibition, our results showed that R443S and L415M acting in concert are capable of reproducing most of the unique properties of hGDH2 almost completely. Therefore, we propose that the preference-determining region is mostly within the corresponding segments 390–448 in hGDH1 and hGDH2, and the amino acid changes at 415 and 443 sites within the antenna domain are responsible for most of the different regulatory properties between the hGDH isozymes.


   FOOTNOTES
 
* This work was supported by Korea Research Foundation Grant KRF-2006-005-J00802), Korea Science and Engineering Foundation Grant R01-2002-000-00125-0, and Asan Institute for Life Sciences University of Ulsan Grant 2006-010. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 To whom correspondence may be addressed: 388-1 Poongnap-2dong, Songpa-gu, Seoul 138-736, Korea. Fax: 82-2-3010-4278; E-mail: swcho{at}amc.seoul.kr. 2To whom correspondence may be addressed: 388-1 Poongnap-2dong, Songpa-gu, Seoul 138-736, Korea. Fax: 82-2-3010-4248; E-mail: jwhuh72{at}amc.seoul.kr.

3 The abbreviations used are: GDH, glutamate dehydrogenase; hGDH, human GDH; HPLC, high performance liquid chromatography. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Yip, K. S. P., Stillman, T. J., Britton, K. L., Artymiuk, P. J., Baker, P. J., Sedelnikova, S. E., Engel, P. C., Pasquo, A., Chiaraluce, R., Consalvi, V., Scandurra, R., and Rice, D. W. (1995) Structure. 3, 1147–1158[Medline] [Order article via Infotrieve]
  2. Knapp, S., de Vos, W. M., Rice, D., and Ladenstein, R. (1997) J. Mol. Biol. 267, 916–932[CrossRef][Medline] [Order article via Infotrieve]
  3. Zaganas, I., and Plaitakis, A. (2002) J. Biol. Chem. 277, 26422–26428[Abstract/Free Full Text]
  4. Yang, S.-J., Huh, J.-W., Hong, H.-N., Kim, T. U., and Cho, S.-W. (2004) FEBS Lett. 562, 59–64[CrossRef][Medline] [Order article via Infotrieve]
  5. Mastorodemos, V., Zaganas, I., Spanaki, C., Bessa, M., and Plaitakis, A. (2005) J. Neurosci. Res. 79, 65–73[CrossRef][Medline] [Order article via Infotrieve]
  6. Kanavouras, K., Mastorodemos, V., Borompokas, N., Spanaki, C., and Plaitakis, A. (2007) J. Neurosci. Res. 85, 1101–1109[CrossRef][Medline] [Order article via Infotrieve]
  7. Smith, T. J., Schmidt, T., Fang, J., Wu, J., Siuzdak, G., and Stanley, C. A. (2002) J. Mol. Biol. 318, 765–777[CrossRef][Medline] [Order article via Infotrieve]
  8. Banerjee, S., Schmidt, T., Fang, J., Stanley, C. A., and Smith, T. J. (2003) Biochemistry 42, 3446–3456[CrossRef][Medline] [Order article via Infotrieve]
  9. Allen, A., Kwagh, J., Fang, J., Stanley, C. A., and Smith, T. J. (2004) Biochemistry 43, 14431–14443[CrossRef][Medline] [Order article via Infotrieve]
  10. Hussain, M. H., Zannis, V. I., and Plaitakis, A. (1989) J. Biol. Chem. 264, 20730–20735[Abstract/Free Full Text]
  11. Gorovitis, R., Avidan, N., Avisar, N., Shaked, I., and Vardimon, L. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 7024–7029[Abstract/Free Full Text]
  12. Plaitakis, A., and Shashidharan, P. (2000) J. Neurol. 247, Suppl. 2, 25–35
  13. Stanley, C. A., Lieu, Y. K., Hus, B. Y., Burlina, A. B., Greenberg, C. R., Hopwood, N. J., Perlman, K., Rich, B. H., Zammarchi, E., and Ponoz, M. (1998) N. Engl. J. Med. 338, 1352–1357[Abstract/Free Full Text]
  14. Tanizawa, Y., Nakai, K., Sasaki, T., Anno, T., Ohta, Y., Inoue, H., Matsuo, K., Koga, M., Furukawa, S., and Oka, Y. (2002) Diabetes 51, 712–717[Abstract/Free Full Text]
  15. Shashidharan, P., Michaelidis, T. M., Robakis, N. K., Kresovali, A., Papamatheakis, J., and Plaitakis, A. (1994) J. Biol. Chem. 269, 16971–16976[Abstract/Free Full Text]
  16. Shashidharan, P., Clarke, D. D., Ahmed, N., Moschonas, N., and Plaitakis, A. (1997) J. Neurochem. 68, 1804–1811[Medline] [Order article via Infotrieve]
  17. Zaganas, I., Spanaki, C., Karpusas, M., and Plaitakis, A. (2002) J. Biol. Chem. 277, 46552–46558[Abstract/Free Full Text]
  18. Hanahan, D. (1983) J. Mol. Biol. 166, 557–580[Medline] [Order article via Infotrieve]
  19. Teller, J. K., Smith, R. J., McPherson, M. J., Engel, P. C., and Guest, J. R. (1992) Eur. J. Biochem. 206, 151–159[Medline] [Order article via Infotrieve]
  20. Studier, F. W., and Moffatt, B. A. (1986) J. Mol. Biol. 189, 113–130[CrossRef][Medline] [Order article via Infotrieve]
  21. Cho, S.-W., Yoon, H.-Y., Ahn, J.-Y., Lee, E.-Y., and Lee, J. (2001) Eur. J. Biochem. 268, 3205–3213[Medline] [Order article via Infotrieve]
  22. Jang, S. H., Kim, A. Y., Bahn, J. H., Eum, W. S., Kim, D. W., Park, J., Lee, K. S., Kang, T.-C., Won, M. H., Kang, J. H., Kwon, O.-S., Yoon, H.-Y., Lee, E.-Y., Cho, S.-W., and Choi, S. Y. (2003) Exp. Mol. Med. 35, 249–256[Medline] [Order article via Infotrieve]
  23. Bradford, M. (1976) Anal. Biochem. 72, 248–254[CrossRef][Medline] [Order article via Infotrieve]
  24. Fersht, A. (1985) Enzyme Structure and Mechanism, pp. 98–120, W. H. Freeman and Co., New York
  25. Julliard, J., and Smith, E. L. (1979) J. Biol. Chem. 254, 3427–3438[Abstract/Free Full Text]
  26. Cho, S.-W., Ahn, J. Y., Lee, J., and Choi, S. Y. (1996) Biochemistry 35, 13907–13913[CrossRef][Medline] [Order article via Infotrieve]
  27. Lee, E. Y., Yoon, H. Y., Ahn, J. Y., Choi, S. Y., and Cho, S.-W. (2001) J. Biol. Chem. 276, 47930–47936[Abstract/Free Full Text]
  28. Burki, F., and Kaessmann, H. (2004) Nat. Genet. 36, 1061–1063[CrossRef][Medline] [Order article via Infotrieve]
  29. Plaitakis, A., Berl, S., and Yahr, M. D. (1982) Science 216, 193–196[Abstract/Free Full Text]
  30. Duvoisin, R. C., Chokroverty, S., Lepore, F., and Nicklas, W. J. (1983) Neurology 33, 1322–1326[Medline] [Order article via Infotrieve]
  31. Konagaya, Y., Konagaya, M., and Takayanagi, T. (1986) J. Neurol. Sci. 74, 231–236[CrossRef][Medline] [Order article via Infotrieve]
  32. Kajiyama, K., Ueno, S., Tatsumi, T., Yorifuji, S., Takahashi, M., and Tarui, S. (1988) J. Neurol. Neurosurg. Psychiatry 51, 1078–1080[Abstract]
  33. Iwattsuji, K., Nakamura, S., and Kameyama, M. (1989) Gerontology 35, 218–224[Medline] [Order article via Infotrieve]
  34. Abe, T., Ishiguro, S. I., Saito, H., Kiyosawa, M., and Tamai, M. (1992) Investig. Ophthalmol. Vis. Sci. 33, 447–452[Abstract/Free Full Text]
  35. Fiermonte, G., Palmieri, L., Todisco, S., Agrimi, G., Palmieri, F., and Walker, J. E. (2002) J. Biol. Chem. 277, 19289–19294[Abstract/Free Full Text]
  36. Plaitakis, A., Spanaki, C., Mastorodemos, V., and Zaganas, I. (2003) Neurochem. Int. 43, 401–410[CrossRef][Medline] [Order article via Infotrieve]
  37. Peterson, P. E., and Smith, T. J. (1999) Structure 7, 769–782[Medline] [Order article via Infotrieve]
  38. Smith, T. J., Peterson, P. E., Schmidt, T., Fang J., and Stanley, C. A. (2001) J. Mol. Biol. 307, 707–720[CrossRef][Medline] [Order article via Infotrieve]
  39. Fang, J., Macmullen, C., Smith, T. J., and Stanley, C. A. (2002) Biochem. J. 363, 81–87[CrossRef][Medline] [Order article via Infotrieve]
  40. Stanley, C. A., Fang, J., Kutyna, K., Hsu, B. Y., Ming, J. E., Glaser, B., and Poncz, M. (2000) Diabetes 49, 667–673[Abstract]
  41. MacMullenm, C., Fang, J., Hsu, B. Y. L., Kelly, A., DeLonlay-Debeney, P., Saudubray, J. M., Ganguly, A., Smith, T. J., and Stanley, C. A. (2001) J. Clin. Endocrinol. Metab. 86, 1782–1787[Abstract/Free Full Text]
  42. Cho, S.-W., Lee, J., and Choi, S. Y. (1995) Eur. J. Biochem. 233, 340–346[Medline] [Order article via Infotrieve]
  43. Plaitakis, A., and Zaganas, I. (2001) J. Neurosci. Res. 66, 899–908[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/27/19510    most recent
M703018200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choi, M.-M.
Right arrow Articles by Huh, J.-W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choi, M.-M.
Right arrow Articles by Huh, J.-W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research